GIOPEM

Pemetrexed is among the promising discoveries of the 21st century that changed treatment paradigm for a sub-population of lung cancer patients.

Pemetrexed is among the promising discoveries of the 21st century that changed treatment paradigm for a sub-population of lung cancer patients.Pemetrexed is a multitargeted antifolate that inhibits atleast three folate dependant enzymes involved in DNA synthesis. It is the first choice chemotherapeutic drug for  advanced or metastatic non-small cell lung cancer (NSCLC) patients with nonsquamous histology.

Indications:

  • For the initial treatment of patients with locally advanced or metastatic nonsquamous non-small cell lung cancer in combination with cisplatin therapy
  • For the maintenance treatment of patients with locally advanced or metastatic nonsquamous non-small cell lung cancer whose disease has not progressed after four cycles of platinum-based first-line chemotherapy
  • For the treatment of patients with locally advanced or metastatic nonsquamous non-small cell lung cancer as a single-agent after prior chemotherapy
  • For the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery in combination with cisplatin

 

Generic Name

Strength

Standard

Type

Packing

Pack Size

Pemetrexed

100 mg

INJ

Vial

 ml

Pemetrexed

500 mg

INJ

Vial

 ml